HRAS and non-small cell lung carcinoma: HRAS-mutant NSCLC (52.9%) had significantly more co-alterations in PI3K/mTOR pathway genes compared to KRAS (32.2%) and NRAS (23.7%) (Figure 2D; p<0.05).